Once Daily 3TC, Efavirenz and ddI for HIV Infection
HIV Infection, AIDS
About this trial
This is an interventional treatment trial for HIV Infection focused on measuring HIV infection, AIDS, Adherence, MEMS caps, Treatment Experienced
Eligibility Criteria
Inclusion Criteria: aged 18 years or more with laboratory evidence of HIV-1 infection ability to understand and provide written informed consent to participate in the study stable on current ART regimen for at least 3 months prior to screening. plasma HIV-RNA less than 400 copies/ml at the screening visit. women of child bearing potential must have a negative serum or urine β-HCG pregnancy test within 14 days prior to week -4 (assessment of study eligibility) Exclusion Criteria: virological failure of a proposed Once daily arm medication a serious medical condition which may compromise the subject's safety, including an active AIDS-defining condition within the previous 6 months known toxicities to any of the proposed Once daily arm medications laboratory abnormalities at screening: serum creatinine greater than twice the upper limit of normal (2 x upper limit of normal (ULN)) AST, ALT or alkaline phosphatase greater than 5 times the ULN lactate greater than 2.5 x ULN haemoglobin less than 9.5 g/dL women who are pregnant or breast-feeding or who, if of child-bearing potential, are not willing to use adequate contraception (including barrier contraception) patients who in the investigator's opinion are unlikely to complete the study
Sites / Locations
- 407 DoctorsRecruiting